Management of Decompensated Cirrhosis

Definition and Importance

The European Association for the Study of the Liver (EASL) defines decompensated cirrhosis as the presence of clinical manifestations such as ascites, variceal hemorrhage, hepatic encephalopathy, and jaundice 1, 2

The American Association for the Study of Liver Diseases (AASLD) recommends diagnostic paracentesis in all patients with new-onset grade 2 or 3 ascites, or those hospitalized for ascites complications or any cirrhosis complication 3
Immediate assessment of airway, breathing, and circulation, with rapid volume replacement using crystalloids to restore hemodynamic stability is crucial 4, 5
A restrictive transfusion strategy with a hemoglobin threshold of 7 g/dL and a target of 7-9 g/dL should be applied to avoid increasing portal pressure 6, 5

Moderate sodium restriction (80-120 mmol/day, equivalent to 4.6-6.9 g of salt) is recommended 3
Avoiding nephrotoxic medications, NSAIDs, and aminoglycosides during decompensation episodes is essential 6

Immediate pharmacological treatment with vasoactive medications (terlipressin, somatostatin, or octreotide) should be initiated upon suspicion of variceal hemorrhage, even before endoscopic confirmation 4, 5
Upper endoscopy should be performed within the first 12 hours of admission 6, 5
Endoscopic variceal ligation is the treatment of choice for esophageal varices 4, 5
Prophylactic antibiotics should be administered immediately and continued for up to 7 days (ceftriaxone 1g/day IV for patients with decompensated cirrhosis) 6, 5

Monitoring for hepatic encephalopathy and treating it with lactulose or lactitol is crucial 6, 4
Identifying and treating precipitating factors (infection, bleeding, medications) is essential 7
Simple tests like animal naming can be used to screen for minimal hepatic encephalopathy 7

Close monitoring of renal function and avoiding nephrotoxic medications is vital 7, 6
In cases of suspected hepatorenal syndrome, following the EASL guidelines' algorithm for management is recommended 7
Renal replacement therapy may be considered as a bridge to transplantation in cases of end-stage renal failure 7

Screening for diabetes in patients with decompensated cirrhosis is necessary due to its high prevalence 7
Insulin therapy is the only evidence-based option for treating type 2 diabetes in this context 7
Initiating treatment in a hospital setting is recommended due to significant glucose variability and hypoglycemia risks 7

Treating the underlying cause is essential and may lead to recompensation of cirrhosis 8
For patients with hepatitis B, using potent nucleoside/nucleotide analogues with a low resistance risk (tenofovir or entecavir) is recommended 8
For patients with hepatitis B-related decompensated cirrhosis, treatment should not be based on ALT levels, as they may be normal in advanced disease 8

Initiating secondary prophylaxis with non-selective beta-blockers and/or endoscopic variceal ligation once bleeding is controlled is recommended 4, 5
Using beta-blockers with caution in patients with severe or refractory ascites is advised 5
Patients with ascites should generally be considered for referral to a liver transplantation program 3

Liver transplantation remains the definitive treatment for patients with decompensated cirrhosis 8
Prolonged and adequate suppression of HBV DNA can stabilize patients and delay or avoid the need for transplantation 8

The American Association for the Study of Liver Diseases recommends starting antiviral therapy immediately if hepatitis B-related, regardless of ALT levels or HBV DNA levels, in patients with decompensated cirrhosis 9
Entecavir 1 mg daily or tenofovir monotherapy should be used as first-line agents due to potent antiviral efficacy and high genetic barrier to resistance in patients with decompensated cirrhosis 10
Interferon-α is absolutely contraindicated in decompensated cirrhosis due to risk of precipitating liver failure and serious infections, according to the American Association for the Study of Liver Diseases 9, 10
Referring all patients with decompensated cirrhosis for transplant evaluation immediately is recommended, as this is the definitive treatment, and antiviral therapy can stabilize patients and improve Child-Turcotte-Pugh scores 9, 10

Patients with decompensated cirrhosis should be managed in institutions capable of handling complications, according to the American Association for the Study of Liver Diseases 9, 10

Delaying antiviral therapy waiting for specific HBV DNA thresholds should be avoided, as any detectable level requires immediate treatment in decompensated cirrhosis, according to the American Association for the Study of Liver Diseases 9
Using interferon under any circumstances in decompensated patients should be avoided, due to risk of precipitating liver failure and serious infections, according to the American Association for the Study of Liver Diseases 9, 10